Kirk M. Druey

Dr. Kirk M. Druey

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2010 in Annals of Internal Medicine
Verified
Journal Article
Open access
KDKirk M. Druey
Kirk M. Druey
PGPhilip R. Greipp
Philip R. Greipp
First described in 1960, the systemic capillary leak syndrome (SCLS) is a rare disease of reversible plasma extravasation and vascular collapse accompanied by hemoconcentration and hypoalbuminemia ... The systemic capillary leak syndrome (SCLS) is a rare disease of reversible plasma extravasation and vascular collapse accompanied by hemoconcentration and hypoalbuminemia. Its cause is unknown, al...

1 January 2012 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
PKPeter Kellman
Peter Kellman
JWJoel R Wilson
Joel R Wilson
HXHui Xue
Hui Xue
WBW Patricia Bandettini
W Patricia Bandettini
SSSujata M Shanbhag
Sujata M Shanbhag
AAAndrew E Arai
Andrew E Arai
Disturbances in the myocardial extracellular volume fraction (ECV), such as diffuse or focal myocardial fibrosis or edema, are hallmarks of heart disease. Diffuse ECV changes are difficult to assess or quantify with cardiovascular magnetic resonance (CMR) using conventional late gadolinium enhancement (LGE), or pre- or post-contrast T1-mapping alone. ECV measurement circumvents factors that confound T1-weighted images or T1-maps, and has been shown to correlate well with diffuse myocardial fibrosis. The goal of this study was to develop and evaluate an automated method for producing a pixel-wise map of ECV that would be adequately robust for clinical work flow.

1 December 2007 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GBGeetanjali Bansal
Geetanjali Bansal
KDKirk M. Druey
Kirk M. Druey
ZXZhihui Xie
Zhihui Xie

3 May 2012 in Blood
Verified
Journal Article
Open access
PDF file
ZXZhihui Xie
Zhihui Xie
CGChandra C. Ghosh
Chandra C. Ghosh
RPRoshni Patel
Roshni Patel
SIShoko Iwaki
Shoko Iwaki
DGDonna Gaskins
Donna Gaskins
KDKirk M. Druey
Kirk M. Druey
The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.

1 September 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KDKirk M. Druey
Kirk M. Druey
SPSamir M. Parikh
Samir M. Parikh

13 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNariamn Balenga
Nariamn Balenga
MKMichael Klichinsky
Michael Klichinsky
ZXZhihui Xie
Zhihui Xie
ECEunice C. Chan
Eunice C. Chan
MZMing Zhao
Ming Zhao
KDKirk M. Druey
Kirk M. Druey
Asthma, a common disorder that affects >250 million people worldwide, is defined by exaggerated bronchoconstriction to inflammatory mediators including acetylcholine (ACh), bradykinin and histamine—also termed airway hyper-responsiveness. Nearly 10% of people with asthma have severe, treatment-resistant disease, which is frequently associated with immunoglobulin-E sensitization to ubiquitous fungi, typically Aspergillus fumigatus (Af). Here we show that a major Af allergen, Asp f13, which is a serine protease, alkaline protease 1 (Alp 1), promotes airway hyper-responsiveness by infiltrating the bronchial submucosa and disrupting airway smooth muscle (ASM) cell-extracellular matrix (ECM) interactions. Alp 1-mediated ECM degradation evokes pathophysiological RhoA-dependent Ca2+ sensitivity and bronchoconstriction. These findings support a pathogenic mechanism in asthma and other lung diseases associated with epithelial barrier impairment, whereby ASM cells respond directly to inhaled environmental allergens to generate airway hyper-responsiveness.